knowledge -WSS

knowledge

author：leisure time 2025-09-27 16:46:44 - browse：6372

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Health care court cases: Humana, Sutter, Novant

WSS

Curing rare childhood diseases will falter unless Congress steps up

My daughter's legacy lives on through her writing, phage therapy

Teladoc has a new CEO, but challenges remain the same

ALS treatment from Biogen, Ionis fails in study

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

The high cost of giving birth even with insurance

WuXi Biologics execs register to lobby as Congress comes for the company

Trump demands the U.S. pay no more for drugs than other countries … again

The United States must get value

The high cost of giving birth even with insurance

ALS patient reclaims some autonomy thanks to wearable 'robot'

Cancer drug shortages should be causing more outrage

Coercive sterilizations revealed by STAT prompt outrage

Moonlake's readout produced a cash windfall. Risks remain

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

focus

Hottest summer in 2,000 years puts focus on extreme heat, health

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Stephen Quake on the Chan Zuckerberg quest to conquer disease

The United States must get value

Obesity drug from Roche shows promise in early study

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

explore

focus

focus

Wikipedia